

| | | | | | |
|---|---|--------------------------|----------------|------------------------|-----------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Complete if Known | | | |
| | | Application Number | 10/544,093 | | |
| | | Filing Date | August 1, 2005 | | |
| | | First Named Inventor | Yednock, Ted | | |
| | | Art Unit | 1649 | | |
| | | Examiner Name | Emch, Gregory | | |
| Sheet | 1 | of | 27 | Attorney Docket Number | 15270C-009820US |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number Kind Code ² (if known) | | | |
| | 945 | 2008/0050367 A1 | 02-28-2008 | Basi et al. | |
| | 944 | 2007/0238154 A1 | 10-11-2007 | Basi et al. | |
| | 943 | 2007/0154480 A1 | 07-05-2007 | Schenk et al. | |
| | 855 | 7,195,761 | 03-27-2007 | Holtzman et al. | |
| | 878 | 7,189,819 | 03-13-2007 | Basi et al. | |
| | 879 | 7,179,892 | 02-20-2007 | Basi et al. | |
| | 946 | 2006/0280743 A1 | 12-14-2006 | Basi et al. | |
| | 880 | 7,014,855 | 03-21-2006 | Schenk | |
| | 881 | 6,982,084 | 01-03-2006 | Schenk | |
| | 686 | 6,972,127 | 12-06-2005 | Schenk | |
| | 879 | 7,179,892 | 02-20-2007 | Basi et al. | |
| | 679 | 2005/0255122 A1 | 11-17-2005 | Schenk | |
| | 680 | 2005/0249727 A1 | 11-10-2005 | Schenk | |
| | 785 | 2005/0249725 A1 | 11-10-2005 | Schenk et al. | |
| | 866 | 6,962,984 | 11-08-2005 | Ishiwata et al. | |
| | 674 | 6,962,707 | 11-08-2005 | Schenk | |
| | 656 | 6,946,135 | 09-20-2005 | Schenk | |
| | 949 | 2005/0196399 A1 | 09-08-2005 | Schenk et al. | |
| | 693 | 2005/0191314 A1 | 09-01-2005 | Schenk | |
| | 713 | 6,936,698 | 08-30-2005 | Taylor | |
| | 716 | 6,933,368 | 08-23-2005 | Co et al. | |
| | 758 | 2005/0169925 A1 | 08-04-2005 | Bardroff et al. | |
| | 892 | 6,923,964 | 08-02-2005 | Schenk | |
| | 685 | 2005/0163788 A1 | 07-28-2005 | Schenk | |
| | 884 | 2005/0152878 A1 | 07-14-2005 | Solomon et al. | |
| | 657 | 6,913,745 | 07-05-2005 | Schenk | |
| | 715 | 2005/0136054 A1 | 06-23-2005 | Adair et al. | |
| | 658 | 6,905,686 | 06-14-2005 | Schenk | |
| | 714 | 2005/0123534 A1 | 06-09-2005 | Adair et al. | |
| | 784 | 2005/0118651 A1 | 06-02-2005 | Basi et al. | |
| | 659 | 6,890,535 | 05-10-2005 | Schenk | |
| | 683 | 2005/0059802 A1 | 03-17-2005 | Schenk et al. | |
| | 684 | 2005/0059591 A1 | 03-17-2005 | Schenk et al. | |
| | 661 | 2005/0009150 A1 | 01-13-2005 | Basi et al. | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./

| | | | | | |
|---|---|--------------------------|----------------|------------------------|-----------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Complete if Known | | | |
| | | Application Number | 10/544,093 | | |
| | | Filing Date | August 1, 2005 | | |
| | | First Named Inventor | Yednock, Ted | | |
| | | Art Unit | 1649 | | |
| | | Examiner Name | Emch, Gregory | | |
| Sheet | 2 | of | 27 | Attorney Docket Number | 15270C-009820US |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number Kind Code ² (if known) | | | |
| | 673 | 6,808,712 | 10-26-2004 | Schenk | |
| | 805 | 2004/0197324 A1 | 10-07-2004 | Jun et al. | |
| | 667 | 6,787,523 | 09-07-2004 | Schenk | |
| | 670 | 6,787,144 | 09-07-2004 | Schenk | |
| | 668 | 6,787,143 | 09-07-2004 | Schenk | |
| | 672 | 6,787,140 | 09-07-2004 | Schenk | |
| | 882 | 6,787,139 | 09-07-2004 | Schenk | |
| | 669 | 6,787,138 | 09-07-2004 | Schenk | |
| | 671 | 6,787,129 | 09-07-2004 | Schenk | |
| | 660 | 2004/0171815 A1 | 09-02-2004 | Schenk et al. | |
| | 783 | 2004/0087777 A1 | 05-06-2004 | Basi et al. | |
| | 782 | 2004/0082762 A1 | 04-29-2004 | Basi et al. | |
| | 849 | 6,727,349 | 04-27-2004 | LaRosa et al. | |
| | 870 | 2003/0207828 A1 | 11-06-2003 | Ishiwata et al. | |
| | 708 | 2003/0039645 A1 | 10-14-2003 | Adair et al. | |
| | 675 | 6,710,226 | 03-23-2004 | Schenk | |
| | 804 | 2003/0202972 A1 | 10-30-2003 | James et al. | |
| | 712 | 6,639,055 | 10-28-2003 | Carter et al. | |
| | 709 | 6,632,927 | 10-14-2003 | Adair et al. | |
| | 748 | 6,610,493 | 08-26-2003 | Citron et al. | |
| | 730 | 2003/0166557 A1 | 09-04-2003 | Minna et al. | |
| | 869 | 2003/0135035 A1 | 07-17-2003 | Shannon | |
| | 883 | 6,582,945 | 06-24-2003 | Raso | |
| | 871 | 2003/0092145 A1 | 05-15-2003 | Jira et al. | |
| | 702 | 6,548,640 | 04-15-2003 | Winter | |
| | 725 | 6,538,124 | 03-25-2003 | Idusogie et al. | |
| | 726 | 6,528,624 | 03-04-2003 | Idusogie et al. | |
| | 710 | 6,407,213 | 06-18-2002 | Carter et al. | |
| | 776 | 6,372,716 | 04-16-2002 | Bush et al. | |
| | 906 | 6,339,068 | 01-15-2002 | Krieg et al. | |
| | 720 | 6,277,375 | 08-21-2001 | Ward | |
| | 777 | 6,270,757 | 08-07-2001 | Warne | |
| | 778 | 6,267,958 | 07-31-2001 | Andya et al. | |
| | 795 | 6,210,671 | 04-03-2001 | Co | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./

| | | | | | |
|---|---|----|--------------------------|------------------------|-----------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | Complete if Known | | |
| | | | Application Number | 10/544,093 | |
| | | | Filing Date | August 1, 2005 | |
| | | | First Named Inventor | Yednock, Ted | |
| | | | Art Unit | 1649 | |
| | | | Examiner Name | Emch, Gregory | |
| Sheet | 3 | of | 27 | Attorney Docket Number | 15270C-009820US |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number Kind Code ² (if known) | | | |
| | 724 | 6,194,551 | 02-27-2001 | Idusogie et al. | |
| | 704 | 6,180,370 | 01-30-2001 | Queen et al. | |
| | 747 | 6,175,057 | 01-16-2001 | Mucke et al. | |
| | 719 | 6,165,745 | 12-26-2000 | Ward et al. | |
| | 723 | 6,121,022 | 09-19-2000 | Presta et al. | |
| | 711 | 6,054,297 | 04-25-2000 | Carter et al. | |
| | 905 | 5,994,083 | 11-30-1999 | Felici et al. | |
| | 722 | 5,869,046 | 02-09-1999 | Presta et al. | |
| | 867 | 5,866,129 | 02-02-1999 | Chang et al. | |
| | 707 | 5,859,205 | 01-12-1999 | Adair et al. | |
| | 860 | 5,858,981 | 01-12-1999 | Schreiber et al. | |
| | 771 | 5,837,268 | 11-17-1998 | Potter et al. | |
| | 885 | 5,798,102 | 08-25-1998 | McMichael et al. | |
| | 779 | 5,770,700 | 06-23-1998 | Webb et al. | |
| | 780 | 5,744,132 | 04-28-1998 | Warne et al. | |
| | 770 | 5,733,548 | 03-31-1998 | Restifo et al. | |
| | 876 | 5,731,284 | 03-24-1998 | Williams | |
| | 642 | 5,702,906 | 12-30-1997 | Rosenthal | |
| | 643 | 5,693,762 | 12-02-1997 | Queen et al. | |
| | 705 | 5,693,761 | 12-02-1997 | Queen et al. | |
| | 721 | 5,677,425 | 10-14-1997 | Bodmer et al. | |
| | 717 | 5,648,260 | 07-15-1997 | Winter et al. | |
| | 924 | 5,624,937 | 04-29-1997 | Reel et al. | |
| | 718 | 5,624,821 | 04-29-1997 | Winter et al. | |
| | 644 | 5,618,920 | 04-08-1997 | Robinson et al. | |
| | 764 | 5,601,827 | 02-11-1997 | Collier et al. | |
| | 706 | 5,585,089 | 12-17-1996 | Queen et al. | |
| | 619 | 5,530,101 | 06-25-1996 | Queen et al. | |
| | 781 | 5,385,887 | 01-31-1995 | Yim et al. | |
| | 645 | 5,258,498 | 11-02-1993 | Huston et al. | |
| | 868 | 5,245,015 | 09-14-1993 | Fung et al. | |
| | 819 | 5,227,159 | 07-13-1993 | Miller | |
| | 703 | 5,225,539 | 07-06-1993 | Winter | |
| | 740 | 4,883,666 | 11-28-1989 | Sabel et al. | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./

| | | | | | |
|---|---|--------------------------|----------------|------------------------|-----------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Complete if Known | | | |
| | | Application Number | 10/544,093 | | |
| | | Filing Date | August 1, 2005 | | |
| | | First Named Inventor | Yednock, Ted | | |
| | | Art Unit | 1649 | | |
| | | Examiner Name | Emch, Gregory | | |
| Sheet | 4 | of | 27 | Attorney Docket Number | 15270C-009820US |

| U.S. PATENT DOCUMENTS | | | | | |
|--------------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number Kind Code ² (if known) | | | |
| | 646 | 4,816,567 | 03-28-1989 | Cabilly et al. | |
| | 647 | 4,816,397 | 03-28-1989 | Boss et al. | |
| U.S. PATENT APPLICATIONS | | | | | |
| Examiner | Cite No. ¹ | Document Number Number Kind Code ² (if known) | Filing Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | 899 | 11/358,951 | 02-22-2006 | Solomon et al. | |
| | 691 | 11/245,524 | 10-07-2005 | Schenk | |
| | 692 | 11/245,916 | 10-07-2005 | Schenk | |
| | 948 | 60/251,892 | 12-06-2000 | Basi et al. | |
| | 762 | 60/080,970 | 01-11-1999 | Schenk | |
| | 761 | 60/079,697 | 03-27-1998 | Weiner et al. | |
| | 763 | 60/067,740 | 12-02-1997 | Schenk | |
| | 760 | 60/067,219 | 12-03-1997 | Weiner et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|-----------------------|---------------------------|---------------------|-----------------------------------|--------------------------------|--|---|--------------------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | 853 | EP | 921 189 | B1 | 01-12-2005 | | | <input type="checkbox"/> |
| | 842 | EP | 1 481 992 | A2, A3 | 12-01-2004 | | | <input type="checkbox"/> |
| | 786 | EP | 758 901 | B1 | 02-26-1997 | | | <input type="checkbox"/> |
| | 787 | EP | 758 248 | B1 | 02-19-1997 | | | <input type="checkbox"/> |
| | 738 | EP | 626 390 | A1 | 11-30-1994 | | | <input type="checkbox"/> |
| | 737 | EP | 620 276 | A1 | 10-19-1994 | | | <input type="checkbox"/> |
| | 802 | EP | 597 101 | A1 | 05-18-1994 | | | <input type="checkbox"/> |
| | 921 | EP | 0 391 714 | A2 | 10-10-1990 | | | <input type="checkbox"/> |
| | 820 | EP | 285 159 | A1 | 10-05-1988 | | | <input type="checkbox"/> |
| | 632 | JP | 07-132033 | A | 05-23-1995 | | | <input type="checkbox"/> |
| | 631 | JP | 62-267297 | A | 11-19-1987 | | | <input type="checkbox"/> |
| | 848 | WO | 05/026211 | A2, A3 | 03-24-2005 | | | <input type="checkbox"/> |
| | 701 | WO | 05/014041 | A2 | 02-17-2005 | | | <input type="checkbox"/> |
| | 757 | WO | 04/108895 | A2, A3 | 12-16-2004 | | | <input type="checkbox"/> |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./

| | | | | | |
|---|---|----|----|--------------------------|-----------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/544,093 |
| | | | | Filing Date | August 1, 2005 |
| | | | | First Named Inventor | Yednock, Ted |
| | | | | Art Unit | 1649 |
| | | | | Examiner Name | Emch, Gregory |
| Sheet | 5 | of | 27 | Attorney Docket Number | 15270C-009820US |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|--------------------------|---------------------------|---------------------|-----------------------------------|--------------------------------|--|---|--------------------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | 935 | WO | 04/080419 | A3 | 09-23-2004 | | | <input type="checkbox"/> |
| | 847 | WO | 04/071408 | A2 | 08-26-2004 | | | <input type="checkbox"/> |
| | 918 | WO | 04/069182 | A2 | 08-19-2004 | | | <input type="checkbox"/> |
| | 797 | WO | 04/055164 | A2 | 07-01-2004 | | | <input type="checkbox"/> |
| | 846 | WO | 04/044204 | A2, A3 | 05-27-2004 | | | <input type="checkbox"/> |
| | 796 | WO | 03/105894 | A1 | 12-24-2003 | | | <input type="checkbox"/> |
| | 845 | WO | 03/072036 | A2, A3 | 09-04-2003 | | | <input type="checkbox"/> |
| | 799 | WO | 03/39485 | A2 | 05-15-2003 | | | <input type="checkbox"/> |
| | 756 | WO | 03/16467 | A2, A3 | 02-27-2003 | | | <input type="checkbox"/> |
| | 803 | WO | 03/16466 | A2 | 02-27-2003 | | | <input type="checkbox"/> |
| | 788 | WO | 03/15691 | A2 | 02-27-2003 | | | <input type="checkbox"/> |
| | 798 | WO | 03/09817 | A2 | 02-06-2003 | | | <input type="checkbox"/> |
| | 827 | WO | 02/96937 | A2 | 12-05-2002 | | | <input type="checkbox"/> |
| | 934 | WO | 02/46237 | A3 | 06-13-2002 | | | <input type="checkbox"/> |
| | 789 | WO | 01/05355 | A2 | 01-25-2001 | | | <input type="checkbox"/> |
| | 772 | WO | 99/10008 | A1 | 03-04-1999 | | | <input type="checkbox"/> |
| | 813 | WO | 97/03192 | A3 | 01-30-1997 | | | <input type="checkbox"/> |
| | 633 | WO | 96/08565 | A2 | 03-21-1996 | | | <input type="checkbox"/> |
| | 923 | WO | 95/23860 | A2 | 09-08-1995 | | | <input type="checkbox"/> |
| | 630 | WO | 95/17085 | A1 | 06-29-1995 | | | <input type="checkbox"/> |
| | 854 | WO | 95/07301 | A1 | 03-16-1995 | | | <input type="checkbox"/> |
| | 696 | WO | 95/06407 | A1 | 03-09-1995 | | | <input type="checkbox"/> |
| | 736 | WO | 94/10569 | A1 | 05-11-1994 | | | <input type="checkbox"/> |
| | 922 | WO | 94/09364 | A1 | 04-28-1994 | | | <input type="checkbox"/> |
| | 814 | WO | 94/00153 | A1 | 01-06-1994 | | | <input type="checkbox"/> |
| | 947 | WO | 92/22653 | A1 | 12-23-1992 | | | <input type="checkbox"/> |
| | 821 | WO | 91/16928 | A1 | 11-14-1991 | | | <input type="checkbox"/> |
| | 648 | WO | 91/09967 | A1 | 07-11-1991 | | | <input type="checkbox"/> |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./

| | | | | | | |
|--|---------------|----|----|--------------------------|-----------------|--|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | | |
| | | | | Application Number | 10/544,093 | |
| | | | | Filing Date | August 1, 2005 | |
| | | | | First Named Inventor | Yednock, Ted | |
| | | | | Art Unit | 1649 | |
| Examiner Name | Emch, Gregory | | | | | |
| Sheet | 6 | of | 27 | Attorney Docket Number | 15270C-009820US | |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|--------------------------|---|--------------------------|--|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² | |
| | 927 | AISEN, P., "Inflammation and Alzheimer's Disease: Mechanisms and Therapeutic Strategies," <u>Gerontology</u> , 43:143-149 (1997). | <input type="checkbox"/> | |
| | 912 | AKIYAMA et al., "The amino-terminally truncated forms of amyloid β -protein in brain macrophages in the ischemic lesions of Alzheimer's disease patients," <u>Neuroscience Letters</u> , 219:115-118 (1996). | <input type="checkbox"/> | |
| | 663 | ALBERTS et al., eds. <i>Molecular Biology of The Cell, Third Edition</i> , chapter 23, pages 1208-1209 (1994). | <input type="checkbox"/> | |
| | 773 | ALBERTS ET AL., <i>Molecular Biology of the Cell, 2nd Edition</i> , pages 266-267, Garland Publishing Inc., New York (1989). | <input type="checkbox"/> | |
| | 649 | AMIT et al., "Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 Å Resolution," <u>Science</u> , 233:747-753 (1986). | <input type="checkbox"/> | |
| | 588 | ANDERSON, J. P., "Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells," <u>Neuroscience Letters</u> , 128(1):126-128 (1991). | <input type="checkbox"/> | |
| | 589 | ANDERSON, M. W., "Amending the amyloid hypothesis," <u>The Scientist</u> , 18(20):28-29 (2004). | <input type="checkbox"/> | |
| | 677 | ANKARCRONA et al., "Biomarkers for apoptosis in Alzheimer's disease," <u>Int. J. Geriatric Psychiatry</u> , 20:101-105 (2005). | <input type="checkbox"/> | |
| | 875 | ARD et al., "Scavenging of Alzheimer's Amyloid β -Protein by Microglia in Culture," <u>J. Neuroscience Research</u> , 43:190-202 (1996). | <input type="checkbox"/> | |
| | 898 | ASKELOF et al., "Protective immunogenicity of two synthetic peptides selected from the amino acid sequence of <i>Bordetella pertussis</i> toxin subunit S1," <u>PNAS</u> , 87:1347-1351 (1990). | <input type="checkbox"/> | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|---|-----------------|----|----|--------------------------|----------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/544,093 |
| | | | | Filing Date | August 1, 2005 |
| | | | | First Named Inventor | Yednock, Ted |
| | | | | Art Unit | 1649 |
| Examiner Name | Emch, Gregory | | | | |
| Attorney Docket Number | 15270C-009820US | | | | |
| Sheet | 7 | of | 27 | | |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|---|--------------------------|--|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² | |
| | 681 | AULD et al., "Alzheimer's disease and the basal forebrain cholinergic system: relations to β -amyloid peptides, cognition, and treatment strategies," <u>Progress in Neurobiol.</u> , 68:209-245 (2002). | <input type="checkbox"/> | |
| | 590 | BACSKAI et al., "Non-Fc-mediated mechanisms are involved in clearance of amyloid- β in vivo by immunotherapy," <u>J. Neurosci.</u> , 22(18):7873-7878 (2002). | <input type="checkbox"/> | |
| | 790 | BALES et al., "Administration of an Anti-A β Fab Fragment to APP ^{V717F} Transgenic Mice Reduces Neuritic Plaque," Abstract P4-396, presented at Poster Session P4: Therapeutics and Therapeutic Strategies-Therapeutic Strategies, Amyloid-Based, <u>Neurology of Aging</u> , 25:S587 (2004). | <input type="checkbox"/> | |
| | 858 | BALES et al., "Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A β antibody," <u>J. Clin. Invest.</u> , 116(3):825-832 (2006). | <input type="checkbox"/> | |
| | 911 | BEN-YEDIDIA et al., "Design of peptide and polypeptide vaccines," <u>Current Opinion in Biotechnology</u> , 8:442-448 (1997). | <input type="checkbox"/> | |
| | 750 | BICKEL et al., "Development and in Vitro Characterization of a Cationized Monoclonal Antibody against β A4 Protein: A Potential Probe for Alzheimer's Disease," <u>Bioconjugate Chem.</u> , 5:119-125 (1994). | <input type="checkbox"/> | |
| | 754 | BLASBERG et al., "Regional Localization of Glioma-associated Antigen Defined by Monoclonal Antibody 81C6 <i>in Vivo</i> : Kinetics and Implications for Diagnosis and Therapy," <u>Cancer Research</u> , 47:4432-4443 (1987). | <input type="checkbox"/> | |
| | 840 | BORENSTEIN, S., "New Alzheimer's vaccine to be tested on people soon, Early experiments on mice halted condition; considered safe for humans," <u>Free Press</u> , 7/23/01. | <input type="checkbox"/> | |
| | 746 | BRAZIL et al., "Effects of Incorporation of Immunoglobulin G and Complement Component C1q on Uptake and Degradation of Alzheimer's Disease Amyloid Fibrils by Microglia," <u>J. Biol. Chem.</u> , 275(22):16941-16947 (2000). | <input type="checkbox"/> | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|--|---|----|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/544,093 |
| | | | | Filing Date | August 1, 2005 |
| | | | | First Named Inventor | Yednock, Ted |
| | | | | Art Unit | 1649 |
| | | | | Examiner Name | Emch, Gregory |
| Sheet | 8 | of | 27 | Attorney Docket Number | 15270C-009820US |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|---|--------------------------|--|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² | |
| | 915 | BRITT et al., "Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice," <u>J. Infect. Dis.</u> , 171:18-25 Abstract (1995). | <input type="checkbox"/> | |
| | 832 | BROADWELL et al., "Serum proteins bypass the blood-brain fluid barriers for extracellular entry to the central nervous system," <u>Exp. Neurol.</u> , 120(2):245-263 (1993). | <input type="checkbox"/> | |
| | 824 | BROOKMEYER et al., "Projections of Alzheimer's Disease in the United States and the Public Health Impact of Delaying Disease Onset," <u>Am. J. Public Health</u> , 88:1337-1342 (1998). | <input type="checkbox"/> | |
| | 791 | BUSSIERE et al., "Morphological Characterization of Thioflavin-S-Positive Amyloid Plaques in Transgenic Alzheimer Mice and Effect of Passive A β Immunotherapy on Their Clearance," <u>Am. J. Pathology</u> , 165(3):987-995 (2004). | <input type="checkbox"/> | |
| | 891 | CASADESUS et al., "The Estrogen Myth: Potential Use of Gonadotropin-Releasing Hormone Agonists for the Treatment of Alzheimer's Disease," <u>Drugs R. D.</u> , 7(3):187-193 (2006). | <input type="checkbox"/> | |
| | 901 | CASEY, S.O., "Posterior Reversible Encephalopathy Syndrome: Utility of Fluid-attenuated Inversion Recovery MR Imaging in the Detection of Cortical and Subcortical Lesions," <u>Amer J Neuroradiol</u> , 21:1199-1206 (2000). | <input type="checkbox"/> | |
| | 823 | CASELL et al., "Demography and Epidemiology of Age-Associated Neuronal Impairment," chapter 4, pages 31-50 from <u>Functional Neurobiology of Aging</u> , Hof et al., eds., Academic Press (2001). | <input type="checkbox"/> | |
| | 932 | CHAKRABARTI et al., "Vaccinia Virus Expression Vector: Coexpression of B-Galactosidase Provides Visual Screening of Recombinant Virus Plaques," <u>Molecular and Cellular Biology</u> , 5(12):3403-3409 (1985). | <input type="checkbox"/> | |
| | 930 | CHANG et al., "Adjuvant activity of incomplete Freund's adjuvant," <u>Advanced Drug Delivery Reviews</u> , 32:173-186 (1998). | <input type="checkbox"/> | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | | |
|--|-----------------|----|----|--------------------------|----------------|--|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | | |
| | | | | Application Number | 10/544,093 | |
| | | | | Filing Date | August 1, 2005 | |
| | | | | First Named Inventor | Yednock, Ted | |
| | | | | Art Unit | 1649 | |
| Examiner Name | Emch, Gregory | | | | | |
| Attorney Docket Number | 15270C-009820US | | | | | |
| Sheet | 9 | of | 27 | | | |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|--------------------------|---|--------------------------|--|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² | |
| | 639 | Chimicon International, "Mouse Anti-Amyloid Beta Protein Monoclonal Antibody," Catalog # MAB1561 (2003-2005). | <input type="checkbox"/> | |
| | 591 | CHROMY et al., "Self-assembly of A β (1-42) into globular neurotoxins," <u>Biochemistry</u> , 42(44):12749-12760 (2003). | <input type="checkbox"/> | |
| | 592 | CITRON et al., "Evidence that the 42- and 40- amino acid forms of amyloid- β protein are generated from the β -amyloid precursor protein by different protease activities," <u>PNAS</u> , 93(23):13170-13175 (1996). | <input type="checkbox"/> | |
| | 593 | CITRON, M., "Alzheimer's disease: treatments in discovery and development," <u>Nat. Neurosci.</u> , 5:1055-1057 (2002). | <input type="checkbox"/> | |
| | 699 | CLAYTON et al., "Synucleins in Synaptic Plasticity and Neurodegenerative Disorders," <u>J. Neurosci. Res.</u> , 58:120-129 (1999). | <input type="checkbox"/> | |
| | 766 | COICO et al., <u>Immunology A Short Course, Fifth Edition</u> , pages 18-24 (2003). | <input type="checkbox"/> | |
| | 925 | Colombian Patent Application No. 98071271, Technical Opinion of Jean Paul Vernot submitted on June 22, 2005 as evidence with the brief amending the nullity action (with English translation) (drafted November 2004). | <input type="checkbox"/> | |
| | 859 | COMERY et al., "Passive Immunization Against β -Amyloid Leads to Acute Cognition Improvement," <u>Society for Neuroscience</u> , abstract, Washington DC, 11/12-16/05. | <input type="checkbox"/> | |
| | 908 | COREY-BLOOM et al., "Clinical features distinguishing large cohorts with possible AD, probable AD, and mixed dementia," <u>J. Am. Geriatr. Soc.</u> , 41(1):31-37 Abstract (1993). | <input type="checkbox"/> | |
| | 687 | COX et al., "Adjuvants---a classification and review of their modes of action," <u>Vaccine</u> , 15(3):248-256 (1997). | <input type="checkbox"/> | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|--|----|----|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/544,093 |
| | | | | Filing Date | August 1, 2005 |
| | | | | First Named Inventor | Yednock, Ted |
| | | | | Art Unit | 1649 |
| | | | | Examiner Name | Emch, Gregory |
| Sheet | 10 | of | 27 | Attorney Docket Number | 15270C-009820US |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|---|--------------------------|--|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² | |
| | 836 | DAS et al., "Reduced effectiveness of A β -42 immunization in APP transgenic mice with significant amyloid deposition," <u>Neurobiology of Aging</u> , 22:721-727 (2001). | <input type="checkbox"/> | |
| | 769 | DAVIS, S. S., "Nasal Vaccines," <u>Advanced Drug Delivery Reviews</u> , 51:21-42 (2001). | <input type="checkbox"/> | |
| | 861 | DE FELICE et al., " β -Amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease," <u>Cell Mol. Neurobiol.</u> , 22(5/6):545-563 (2002). | <input type="checkbox"/> | |
| | 893 | DE LA CRUZ et al., "Immunogenicity [sic] and Epitope Mapping of Foreign Sequences via Genetically Engineered Filamentous Phage," <u>J Biol Chem</u> , 263(9):4318-4322 (1988). | <input type="checkbox"/> | |
| | 689 | DE LUSTIG et al., "Peripheral Markers and Diagnostic Criteria in Alzheimer's Disease: Critical Evaluations," <u>Rev. In Neurosciences</u> , 5:213-225 (1994). | <input type="checkbox"/> | |
| | 594 | DEMATTOIS et al., "Brain to plasma amyloid- β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease," <u>Science</u> , 295(5563):2264-2267 (2002). | <input type="checkbox"/> | |
| | 745 | DEWITT et al., "Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease," <u>Experimental Neurology</u> , 149:329-340 (1998). | <input type="checkbox"/> | |
| | 698 | Dictionary.com definition of "prophylactic", pages 1-3 downloaded from internet 10/12/05. | <input type="checkbox"/> | |
| | 735 | DI MARTINO et al., "Production and Characterization of Antibodies to Mouse Scrapie-Amyloid Protein Elicited by Non-carrier Linked Synthetic Peptide Immunogens," <u>J. Molecular Recognition</u> , 4(2-3):85-91 (1991). | <input type="checkbox"/> | |
| | 862 | DISIS et al., "Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines," <u>Blood</u> , 88(1):202-210 (1996). | <input type="checkbox"/> | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|---|---------------|----|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/544,093 |
| | | | | Filing Date | August 1, 2005 |
| | | | | First Named Inventor | Yednock, Ted |
| | | | | Art Unit | 1649 |
| Examiner Name | Emch, Gregory | | | | |
| Sheet | 11 | of | 27 | Attorney Docket Number | 15270C-009820US |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|--------------------------|---|--------------------------|--------------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² | |
| | 595 | DODART et al., "Immunization reverses memory deficits without reducing brain A β burden in Alzheimer's disease model," <u>Nat. Neurosci.</u> , 5(5):452-457 (2002). | <input type="checkbox"/> | |
| | 596 | DODEL et al., "Immunotherapy for Alzheimer's disease," <u>Lancet Neurol.</u> , 2(4):215-220 (2003). | <input type="checkbox"/> | |
| | 597 | DOVEY et al., "Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain," <u>J. Neurochem.</u> , 76(1):173-181 (2001). | <input type="checkbox"/> | |
| | 910 | DREW et al., "Vaccination by cholera toxin conjugated to a herpes simplex virus type 2 glycoprotein D peptide," <u>Journal of General Virology</u> , 73:2357-2366 (1992). | <input type="checkbox"/> | |
| | 817 | DU et al., " α_2 -Macroglobulin as a β -Amyloid Peptide-Binding Plasma Protein," <u>J. Neurochemistry</u> , 69(1):299-305 (1997). | <input type="checkbox"/> | |
| | 598 | DUFF et al., "Increased amyloid- β 42(43) in brains of mice expressing mutant presenilin 1," <u>Nature</u> , 383(6602):710-713 (1996). | <input type="checkbox"/> | |
| | 920 | Ecuador Patent Application No. SP 98-2764, English translation of Expert Report submitted April 19, 2007 in support of the Appeal filed on July 29, 2005. | <input type="checkbox"/> | |
| | 599 | ERIKSEN et al., "NSAIDs and enantiomers of flurbiprofen target γ -secretase and lower A β 42 in vivo," <u>J. Clin. Invest.</u> , 112(3):440-449 (2003). | <input type="checkbox"/> | |
| | 811 | European Search Report of 5/22/06 for European Application 06075704.4-2107. | <input type="checkbox"/> | |
| | 812 | European Search Report of 5/22/06 for European Application 06075479.3-2107. | <input type="checkbox"/> | |
| | 852 | European Search Report of 1/16/07 for European Application 04776252.1-2405. | <input type="checkbox"/> | |
| Examiner Signature | | | | Date Considered |

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|---|----|----|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/544,093 |
| | | | | Filing Date | August 1, 2005 |
| | | | | First Named Inventor | Yednock, Ted |
| | | | | Art Unit | 1649 |
| | | | | Examiner Name | Emch, Gregory |
| Sheet | 12 | of | 27 | Attorney Docket Number | 15270C-009820US |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|--------------------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | 942 | European Examination Report of 03/09/2007 for European Application 01995364.5-1222. | <input type="checkbox"/> |
| | 941 | European Examination Report of 09/26/2007 for European Application 04720353.4-1222. | <input type="checkbox"/> |
| | 940 | European Examination Report of 10/08/2007 for European Application 01995364.5-1222. | <input type="checkbox"/> |
| | 600 | FINDEIS, M. A., "Approaches to discovery and characterization of inhibitors of amyloid β -peptide polymerization," <u>Biochem. Biophys. Acta</u> , 1502(1):76-84 (2000). | <input type="checkbox"/> |
| | 650 | FOOTE et al., "Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops," <u>J. Mol. Biol.</u> , 224:487-499 (1992). | <input type="checkbox"/> |
| | 830 | FOX et al., "Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease," <u>Brain</u> , 121:1631-1639 (1998). | <input type="checkbox"/> |
| | 601 | FRENKEL et al., "Reduction of β -amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization," <u>Vaccine</u> , 21(11-12):1060-1065 (2003). | <input type="checkbox"/> |
| | 602 | FRENKEL et al., "Towards Alzheimer's β -amyloid vaccination," <u>Biologicals</u> , 29(3-4):243-247 (2001). | <input type="checkbox"/> |
| | 831 | FUKUTANI et al., "Cerebellar pathology in sporadic and familial Alzheimer's disease including APP 717 (Val->Ile) mutation cases: A morphometric investigation," <u>J. Neurologic Sci.</u> , 149:177-184 (1997). | <input type="checkbox"/> |
| | 603 | GELINAS et al., "Immunotherapy for Alzheimer's disease," <u>PNAS</u> , 101(suppl. 2):14657-14662 (2004). | <input type="checkbox"/> |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|---|----|----|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/544,093 |
| | | | | Filing Date | August 1, 2005 |
| | | | | First Named Inventor | Yednock, Ted |
| | | | | Art Unit | 1649 |
| | | | | Examiner Name | Emch, Gregory |
| Sheet | 13 | of | 27 | Attorney Docket Number | 15270C-009820US |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|--------------------------|---|--------------------------|--------------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² | |
| | 634 | Genbank Accession number AAB48800, "Anti-DNA immunoglobulin light chain IgG [Mus musculus]," 09/14/01. | <input type="checkbox"/> | |
| | 635 | Genbank Accession number CAA46659, "IgE antibody light chain(VJ)," 06/15/93. | <input type="checkbox"/> | |
| | 636 | Genbank Accession number X65775.1, "M.musculus DNA for IgE antibody light chain (VJ)," 06/15/93. | <input type="checkbox"/> | |
| | 637 | Genbank Accession number AAD26773, "Immunoglobulin heavy chain VH3609-JH3 region [Mus musculus]," 04/22/99. | <input type="checkbox"/> | |
| | 873 | GEYLIS et al., "Immunotherapy of Alzheimer's disease 9AD): From murine models to anti-amyloid beta 9Ab) human monoclonal antibodies," <u>Autoimmunity Rev.</u> , 5:33-39 (2000). | <input type="checkbox"/> | |
| | 902 | GILMAN, S. et al., "Clinical Effects of A β Immunization (AN1792) in Patients with AD in an Interrupted Trial," <u>Neurology</u> , 64:1553-1562 (2005). | <input type="checkbox"/> | |
| | 604 | GONG et al., "Alzheimer's disease-affected brain: presence of oligomeric A β ligands (ADDLs) suggests a molecular basis for reversible memory loss," <u>PNAS</u> , 100(18):10417-10422 (2003). | <input type="checkbox"/> | |
| | 605 | GREENBERG et al., "Alzheimer disease's double-edged vaccine," <u>Nat. Med.</u> , 9(4):389-390 (2003). | <input type="checkbox"/> | |
| | 896 | GROSS et al., "Microvascular specializations promoting rapid interstitial solute dispersion in nucleus tractus solitarius," <u>Am J Physiol Regul Integr Comp Physiol</u> , 259:R1131-R1138 (1990). | <input type="checkbox"/> | |
| | 694 | GUPTA et al., "Adjuvants for human vaccines—current status, problems, and future prospects," <u>Vaccine</u> , 13(14):1263-1275 (1995). | <input type="checkbox"/> | |
| | 606 | HAASS, C., "New hope for Alzheimer disease vaccine," <u>Nat Med.</u> , 8(11):1195-1196 (2002). | <input type="checkbox"/> | |
| Examiner Signature | | | | Date Considered |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|--|----|----|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/544,093 |
| | | | | Filing Date | August 1, 2005 |
| | | | | First Named Inventor | Yednock, Ted |
| | | | | Art Unit | 1649 |
| | | | | Examiner Name | Emch, Gregory |
| Sheet | 14 | of | 27 | Attorney Docket Number | 15270C-009820US |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|--------------------------|---|--------------------------|--|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² | |
| | 807 | HARA et al., "Development of a safe oral A β vaccine using recombinant adeno-associated virus vector for Alzheimer's disease," <u>J. Alzheimer's Disease</u> , 6:483-488 (2004). | <input type="checkbox"/> | |
| | 664 | HARLOW et al., eds., <i>Antibodies: A Laboratory Manual</i> , pages 71-82 (1998). | <input type="checkbox"/> | |
| | 931 | HARLOW et al., eds., <i>Antibodies: A Laboratory Manual</i> , page 98 (1998). | <input type="checkbox"/> | |
| | 741 | HIRSCHFIELD et al., "Amyloidosis: new strategies for treatment," <u>Int. J. Biochem. & Cell Biol.</u> , 35:1608-1613 (2003). | <input type="checkbox"/> | |
| | 607 | HOCK et al., "Generation of antibodies specific for β -amyloid by vaccination of patients with Alzheimer disease," <u>Nat. Med.</u> , 8(11):1270-1275 (2002). | <input type="checkbox"/> | |
| | 662 | IDA et al., "Analysis of Heterogeneous β A4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay," <u>J. Biol. Chem.</u> , 271(37):22908-22914 (1996). | <input type="checkbox"/> | |
| | 887 | IDUSOGIE et al., "Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc," <u>J. Immunology</u> , 164:4178-4184 (2000). | <input type="checkbox"/> | |
| | 608 | IRIZARRY et al., "Alzheimer disease therapeutics," <u>J. Neuropathol. Exp. Neurol.</u> , 60(10):923-928 (2001). | <input type="checkbox"/> | |
| | 929 | JANSEN et al., "Use of Highly Encapsulated <i>Streptococcus pneumoniae</i> Strains in a Flow-Cytometric Assay for Assessment of the Phagocytic Capacity of Serotype-Specific Antibodies," <u>Clinical & Diagnostic Lab. Immunol.</u> , 5(5):703-710 (1998). | <input type="checkbox"/> | |
| | 609 | JANUS et al., "Transgenic mouse models of Alzheimer's Disease," <u>Physiol. Behav.</u> , 73(5):873-886 (2001). | <input type="checkbox"/> | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|--|----|----|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/544,093 |
| | | | | Filing Date | August 1, 2005 |
| | | | | First Named Inventor | Yednock, Ted |
| | | | | Art Unit | 1649 |
| | | | | Examiner Name | Emch, Gregory |
| Sheet | 15 | of | 27 | Attorney Docket Number | 15270C-009820US |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|--------------------------|---|--------------------------|--|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² | |
| | 640 | JUNG et al., "Alzheimer's Beta-amyloid Precursor Protein Is Expressed on the Surface of Immediately Ex Vivo Brain Cells: a Flow Cytometric Study," <u>J. Neurosci. Res.</u> , 46(3):336-348 (1996). | <input type="checkbox"/> | |
| | 792 | KAJKOWSKI et al., "β-Amyloid Peptide-induced Apoptosis Regulated by a Novel Protein Containing a G Protein Activation Module," <u>J. Biol. Chem.</u> , 276(22):18748-18756 (2001). | <input type="checkbox"/> | |
| | 834 | KALBACK et al., "APP Transgenic Mice Tg2576 Accumulate Aβ Peptides That Are Distinct from the Chemically Modified and Insoluble Peptides Deposited in Alzheimer's Disease Senile Plaques," <u>Biochemistry</u> , 41:922-928 (2002). | <input type="checkbox"/> | |
| | 729 | KASCSAK et al., "Mouse Polyclonal and Monoclonal Antibody to Scrapie-Associated Fibril Proteins," <u>J. Virology</u> , 61(12):3688-3693 (1987). | <input type="checkbox"/> | |
| | 895 | KHATOON et al., "Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer's disease and control brains," <u>FEBS Letters</u> , 351:80-84 (1994). | <input type="checkbox"/> | |
| | 863 | KIMCHI et al., "Analysis of cerebral amyloid angiopathy in a transgenic mouse model of Alzheimer disease using in vivo multiphoton microscopy," <u>J. Neuropath Exp. Neurol.</u> , 60(3):274-279 (2001). | <input type="checkbox"/> | |
| | 843 | KLYUBIN et al., "Anti-Aβ Antibodies Prevent Block of Long-Term Potentiation In the CA1 Area of Rat Hippocampus <i>InVivo</i> by naturally Produced Aβ Oligomers," <u>Neurobiology of Aging</u> , 25:S224-S225, abstract P2-004, pages S224-S225 (2004). | <input type="checkbox"/> | |
| | 628 | KOFLER et al., "Mechanism of Allergic Cross-Reactions--III. cDNA Cloning and Variable-Region Sequence Analysis of Two IgE Antibodies Specific for Trinitrophenyl," <u>Mol. Immunology</u> , 29(2):161-166 (1992). | <input type="checkbox"/> | |
| | 794 | KOFLER et al., "Immunoglobulin κ Light Chain Variable Region Gene Complex Organization and Immunoglobulin Genes Encoding Anti-DNA Autoantibodies in Lupus Mice," <u>J. Clin. Invest.</u> , 82:852-860 (1988). | <input type="checkbox"/> | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|--|----|----|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/544,093 |
| | | | | Filing Date | August 1, 2005 |
| | | | | First Named Inventor | Yednock, Ted |
| | | | | Art Unit | 1649 |
| | | | | Examiner Name | Emch, Gregory |
| Sheet | 16 | of | 27 | Attorney Docket Number | 15270C-009820US |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|---|--------------------------|--|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² | |
| | 627 | KRISHNAN et al., "Correlation Between the Amino Acid Position of Arginine in VH-CDR3 and Specificity for Native DNA Among Autoimmune Antibodies ^{1,2} ," <u>J. Immunol.</u> , 157(6):2430-2439 (1996). | <input type="checkbox"/> | |
| | 826 | KUBY, J., eds., page 123 from <i>Immunology, Third Edition</i> , W.H. Freeman & co., (1997). | <input type="checkbox"/> | |
| | 888 | KUBY, J., eds., pages 108-109, 131-132 from <i>Immunology, Third Edition</i> , W.H. Freeman & co., (1997). | <input type="checkbox"/> | |
| | 695 | KUO et al., "Water-soluble A β (N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains," <u>J. Biol. Chem.</u> , 271(8):4077-4081 (1996). | <input type="checkbox"/> | |
| | 833 | KUO et al., "Comparative Analysis of Amyloid- β Chemical Structure and Amyloid Plaque Morphology of Transgenic Mouse and Alzheimer's Disease Brains," <u>J. Biol. Chem.</u> , 276(16):12991-12998 (2001). | <input type="checkbox"/> | |
| | 734 | KURASHIMA et al., "Production of Monoclonal Antibody against Amyloid Fibril Protein and Its Immunohistochemical Application," <u>Appl. Pathol.</u> , 3(1-2):39-54 (1985). | <input type="checkbox"/> | |
| | 816 | LaDu et al., "Isoform-specific Binding of Apolipoprotein E to β -Amyloid," <u>J. Biol. Chem.</u> , 269(38):23403-23406 (1994). | <input type="checkbox"/> | |
| | 651 | LANDOLFI et al., "The Integrity of the Ball-and Socket Joint Between V and C Domains Is Essential for Complete Activity of a Humanized Antibody," <u>J. Immunology</u> , 166(3):1748-1754 (2001). | <input type="checkbox"/> | |
| | 755 | LAVIE et al., "EFRH-Phage Immunization of Alzheimer's Disease Animal Model Improves Behavioral Performance in Morris Water Maze Trials," <u>J. Molecular Neuroscience</u> , 24:105-113 (2004). | <input type="checkbox"/> | |
| | 743 | LICASTRO et al., "Is immunotherapy an effective treatment for Alzheimer's disease?," <u>Immunity & Aging</u> , 1:1-2 (2004). | <input type="checkbox"/> | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|--|----|----|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/544,093 |
| | | | | Filing Date | August 1, 2005 |
| | | | | First Named Inventor | Yednock, Ted |
| | | | | Art Unit | 1649 |
| | | | | Examiner Name | Emch, Gregory |
| Sheet | 17 | of | 27 | Attorney Docket Number | 15270C-009820US |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|--------------------------|---|--------------------------|--|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² | |
| | 727 | LINKE, "Monoclonal antibodies against amyloid fibril protein AA. Production, specificity, and use for immunohistochemical localization and classification of AA-type amyloidosis," <u>J. Histochemistry and Cytochemistry</u> , 32(3):322-328 (1982). | <input type="checkbox"/> | |
| | 889 | LIU et al., "Amyloid β peptide alters intracellular vesicle trafficking and cholesterol homeostasis," <u>Proc. Natl. Acad. Sci.</u> , 95:13266-13271 (1998). | <input type="checkbox"/> | |
| | 665 | LO et al., "High level expression and secretion of Fc-X fusion proteins in mammalian cells," <u>Protein Engineering</u> , 11(6):495-500 (1998). | <input type="checkbox"/> | |
| | 904 | MAMIKONYAN et al., "Anti-A β_{1-11} Antibody Binds to Different β -Amyloid Species, Inhibits Fibril Formation, and Disaggregates Preformed Fibrils but Not the Most Toxic Oligomers," <u>J Biol Chem</u> , 282(31) 22376-22386 (2007). | <input type="checkbox"/> | |
| | 666 | MANDEL et al., "Clinical trials in neurological disorders using AAV vectors: promises and challenges," <u>Curr. Opin. Mol. Ther.</u> , 6(5):482-490 (2004). | <input type="checkbox"/> | |
| | 913 | MANNING et al., "Genetic Immunization with Adeno-Associated Virus Vectors Expressing Herpes Simplex Virus Type 2 Glycoproteins B and D," <u>Journal of Virology</u> , 71(10):7960-7962 (1997). | <input type="checkbox"/> | |
| | 742 | MANOJ et al., "Approaches to Enhance the Efficacy of DNA Vaccines," <u>Critical Rev. Clin. Lab. Sci.</u> , 41(1):1-39 (2004). | <input type="checkbox"/> | |
| | 731 | MARHAUG et al., "Monoclonal hybridoma antibodies to human amyloid related protein SAA," <u>Clin. Exp. Immunol.</u> , 50(2):390-396 (1982). | <input type="checkbox"/> | |
| | 744 | MAROTTA et al., "Overexpression of amyloid precursor protein A4 (β -amyloid) immunoreactivity in genetically transformed cells: Implications for a cellular model of Alzheimer amyloidosis," <u>PNAS</u> , 86:337-341 (1989). | <input type="checkbox"/> | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|---|----|----|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/544,093 |
| | | | | Filing Date | August 1, 2005 |
| | | | | First Named Inventor | Yednock, Ted |
| | | | | Art Unit | 1649 |
| | | | | Examiner Name | Emch, Gregory |
| Sheet | 18 | of | 27 | Attorney Docket Number | 15270C-009820US |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|---|--------------------------|--|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² | |
| | 610 | MATTSON et al., "Good and bad amyloid antibodies," <u>Science</u> , 301(5641):1845-1849 (2003). | <input type="checkbox"/> | |
| | 732 | MAURY et al., "Immunohistochemical Localization of Amyloid in Finnish Hereditary Amyloidosis with Antibodies to Gelsolin Peptides," <u>Laboratory Investigation</u> , 64(3):400-404 (1991). | <input type="checkbox"/> | |
| | 611 | MCLAURIN et al., "Therapeutically effective antibodies against amyloid- β peptide target amyloid- β residues and 4-10 and inhibit cytotoxicity and fibrillogenesis," <u>Nat Med.</u> , 8(11):1263-1269 (2002). | <input type="checkbox"/> | |
| | 822 | Merriam-Webster online medical dictionary, entry for "cure", accessed September 5, 2006. | <input type="checkbox"/> | |
| | 612 | MONSONEGO et al., "Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer's disease," <u>J. Clin. Invest.</u> , 112(3):415-422 (2003). | <input type="checkbox"/> | |
| | 613 | MONSONEGO et al., "Immunotherapeutic approaches to Alzheimer's disease," <u>Science</u> , 302(5646):834-838 (2003). | <input type="checkbox"/> | |
| | 886 | MORGAN et al., "The N-terminal end of the C ₂ domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc γ RII and Fc γ RII binding," <u>Immunology</u> , 86:319-324 (1995). | <input type="checkbox"/> | |
| | 841 | OKIE, S., "Promising Vaccine Targets Ravager of Minds," <u>Washington Post</u> , page A01, 5/8/01. | <input type="checkbox"/> | |
| | 808 | OKURA et al., "Nonviral A β DNA vaccine therapy against Alzheimer's disease: Long-term effect and safety," <u>PNAS</u> , 103(25):9619-9624 (2006). | <input type="checkbox"/> | |
| | 652 | ORLANDI et al., "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," <u>PNAS</u> , 86:3833-3837 (1989). | <input type="checkbox"/> | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|--|----|----|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/544,093 |
| | | | | Filing Date | August 1, 2005 |
| | | | | First Named Inventor | Yednock, Ted |
| | | | | Art Unit | 1649 |
| | | | | Examiner Name | Emch, Gregory |
| Sheet | 19 | of | 27 | Attorney Docket Number | 15270C-009820US |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|--------------------------|---|--------------------------|--------------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² | |
| | 614 | PAGANETTI et al., "Amyloid precursor protein truncated at any of the γ -secretase sites is not cleaved to β -amyloid," <i>J. Neurosci. Res.</i> , 46(3):283-293 (1996). | <input type="checkbox"/> | |
| | 615 | PALLITTO et al., "Recognition sequence design for peptidyl modulators of β -amyloid aggregation and toxicity," <i>Biochemistry</i> , 38(12):3570-3578 (1999). | <input type="checkbox"/> | |
| | 654 | PANKA et al., "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies," <i>PNAS</i> , 85:3080-3084 (1998). | <input type="checkbox"/> | |
| | 829 | PARDRIDGE et al., "The Blood-Brain Barrier: Bottleneck in Brain Drug Development," <i>J. Am. Soc. Exp. Neurotherapeutics</i> , 2:3-14 (2005). | <input type="checkbox"/> | |
| | 682 | PARNETTI et al., "Cognitive Enhancement Therapy for Alzheimer's Disease, The Way Forward," <i>Drugs</i> , 53(5):752-768 (1997). | <input type="checkbox"/> | |
| | 653 | PAUL, W. E., eds., <i>Fundamental Immunology</i> , Third Edition, pages 292-295, Raven Press, New York (1993). | <input type="checkbox"/> | |
| | 933 | PCT International Preliminary Examination Report of 02/09/2004 for application PCT/US01/46587. | <input type="checkbox"/> | |
| | 919 | PCT Written Opinion of 12/14/04 for application PCT/US04/02856. | <input type="checkbox"/> | |
| | 937 | PCT International Preliminary Report on Patentability (Chapter I) of 09/16/2005 with Written Opinion of 05/09/2005 for application PCT/US04/007503. | <input type="checkbox"/> | |
| | 806 | PCT Search Report of 8/11/06 for application PCT/US2006/002837. | <input type="checkbox"/> | |
| | 850 | PCT Search Report of 8/8/06 for application PCT/US2005/045515. | <input type="checkbox"/> | |
| Examiner Signature | | | | Date Considered |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | | |
|---|-----------------|----|----|--------------------------|----------------|--|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | | |
| | | | | Application Number | 10/544,093 | |
| | | | | Filing Date | August 1, 2005 | |
| | | | | First Named Inventor | Yednock, Ted | |
| | | | | Art Unit | 1649 | |
| Examiner Name | Emch, Gregory | | | | | |
| Attorney Docket Number | 15270C-009820US | | | | | |
| Sheet | 20 | of | 27 | | | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|--------------------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | 938 | PCT International Preliminary Report on Patentability (Chapter II) of 04/27/2006 for application PCT/US04/007503. | <input type="checkbox"/> |
| | 872 | PCT Search Report of 4/6/06 and Written Opinion of 4/8/06 for application PCT/US04/44093. | <input type="checkbox"/> |
| | 903 | PCT Search Report of 10/01/2007 and Written Opinion of 10/01/2007 for application PCT/US07/09499. | <input type="checkbox"/> |
| | 774 | PEETERS et al., "Comparison of four bifunctional reagents for coupling peptides to proteins and the effect of the three moieties on the immunogenicity of the conjugates," <u>J. Immunological Methods</u> , 120:133-143 (1989). | <input type="checkbox"/> |
| | 890 | PEREZ et al., "The β -Amyloid Precursor Protein of Alzheimer's Disease Enhances Neuron Viability and Modulates Neuronal Polarity," <u>J. Neurosci.</u> , 17(24):9407-9414 (1997). | <input type="checkbox"/> |
| | 616 | PFEIFER et al., "Cerebral hemorrhage after passive anti-A β immunotherapy," <u>Science</u> , 298(5597):1379 (2002). | <input type="checkbox"/> |
| | 733 | PHELPS et al., "Development and Characterization of Monoclonal Antibodies Specific for Amylin," <u>Hybridoma</u> , 15(5):379-386 (1996). | <input type="checkbox"/> |
| | 864 | PIERA et al., "Cytokines as adjuvants: effects on the immunogenicity of NeuAc alpha 2-GalNAc alpha-O-Ser/Thr (sialyl-Tn)," <u>Int. J. Cancer</u> , 55(1):148-152 (1993). | <input type="checkbox"/> |
| | 877 | PLUCKTHUN, A., "Mono- and Bivalent Antibody Fragments Produced in <i>Escherichia coli</i> : Engineering, Folding and Antigen Binding," <u>Immunological Reviews</u> , 130:151-188 (1992). | <input type="checkbox"/> |
| | 837 | Press Release, "Alzheimer's vaccine developer awarded Potamkin Prize," American Academy of Neurology, 5/7/01. | <input type="checkbox"/> |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|--|---------------|----|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/544,093 |
| | | | | Filing Date | August 1, 2005 |
| | | | | First Named Inventor | Yednock, Ted |
| | | | | Art Unit | 1649 |
| Examiner Name | Emch, Gregory | | | | |
| Sheet | 21 | of | 27 | Attorney Docket Number | 15270C-009820US |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|--------------------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | 751 | PROBERT et al., "Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor α ," <u>PNAS</u> , 92:11294-11298 (1995). | <input type="checkbox"/> |
| | 809 | QU et al., "A β ₄₂ gene vaccination reduces brain amyloid plaque burden in transgenic mice," <u>J. Neurological Sciences</u> , 244:151-158 (2006). | <input type="checkbox"/> |
| | 641 | RACKE et al., "Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of amyloid β ," <u>J. Neurosci.</u> , 25(3):629-636 (2005). | <input type="checkbox"/> |
| | 928 | RAMMENSEE, H.G., "Chemistry of peptides associated with MHC class I and class II molecules," <u>Current Opinion in Immunology</u> , 7:85-96 (1995). | <input type="checkbox"/> |
| | 638 | Research Corporation Technology News, "THP and SangStat Partner to Develop Humanized Polyclonal Antibody Drugs," 11/11/02. | <input type="checkbox"/> |
| | 626 | "Researchers Develop Blood Test to Diagnose Alzheimer's- Type Changes in Mice," downloaded from www.businesswire.com on 12/15/04. | <input type="checkbox"/> |
| | 926 | RODRIGUEZ et al., "Enfermedad de Alzheimer. Situación Actual y Estrategias Terapéuticas" (Alzheimer Disease: present situation and therapeutic strategies), <u>Rev Cubana Med</u> [online], 38(2):134-142 (1999). | <input type="checkbox"/> |
| | 838 | ROSENBERG, R. N., "The Potamkin Prize for Pick's, Alzheimer's Disease and Related Disorders," pages 1-5. | <input type="checkbox"/> |
| | 865 | ROSES, A.D., "Apoplipoprotein E alleles as risk factors in Alzheimer's disease," <u>Annu. Rev. Med.</u> , 47:387-400 (1996). | <input type="checkbox"/> |
| | 655 | RUDIKOFF et al., "Single amino acid substitution altering antigen-binding specificity," <u>PNAS</u> , 79:1979-1983 (1982). | <input type="checkbox"/> |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|--|----|----|----|--------------------------|-----------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/544,093 |
| | | | | Filing Date | August 1, 2005 |
| | | | | First Named Inventor | Yednock, Ted |
| | | | | Art Unit | 1649 |
| | | | | Examiner Name | Emch, Gregory |
| Sheet | 22 | of | 27 | Attorney Docket Number | 15270C-009820US |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|--------------------------|---|--------------------------|--|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² | |
| | 851 | SALDANHA et al., "A single backmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells," <u>Molecular Immunology</u> , 36:709-719 (1999). | <input type="checkbox"/> | |
| | 759 | SCHENK et al., "Current progress in beta-amyloid immunotherapy," <u>Curr. Opin. Immunology</u> , 16(5):599-606 (2004). | <input type="checkbox"/> | |
| | 617 | SCHMID, R. É., "Study suggest Alzheimer vaccine fix," from www.msnbc.com/news, pages 1-5 (2002). | <input type="checkbox"/> | |
| | 768 | SCHMITT et al., "Interactions of the alzheimer β amyloid fragment ₍₂₅₋₃₅₎ with peripheral blood dendritic cells," <u>Mechanisms of Ageing and Development</u> , 94:223-232 (1997). | <input type="checkbox"/> | |
| | 629 | SEIDL et al., "Predominant V _H genes expressed in innate antibodies are associated with distinctive antigen-binding sites," <u>PNAS</u> , 96:2262-2267 (1999). | <input type="checkbox"/> | |
| | 618 | SELKOE, D. J., "Alzheimer's disease is a synaptic failure," <u>Science</u> , 298(5594):789-791 (2002). | <input type="checkbox"/> | |
| | 622 | SERGEANT et al., "Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach," <u>J. Neurochem.</u> , 85(6):1581-1591 (2003). | <input type="checkbox"/> | |
| | 856 | SEUBERT et al., "Antibody Capture of Soluble A β does not Reduce Cortical A β Amyloidosis in the PDAPP Mouse," <u>Neurodegenerative Diseases</u> , 5:65-71 (2008). | <input type="checkbox"/> | |
| | 818 | SHINKAI et al., "Amyloid β -Proteins 1-40 and 1-42(43) in the Soluble Fraction of Extra- and Intracranial Blood Vessels," <u>Ann. Neurol.</u> , 38:421-428 (1995). | <input type="checkbox"/> | |
| | 828 | Signet Laboratories, Inc., Product data sheet for mouse monoclonal clone 6E10, revised 7/13/05. | <input type="checkbox"/> | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|--|-----------------|----|----|--------------------------|----------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/544,093 |
| | | | | Filing Date | August 1, 2005 |
| | | | | First Named Inventor | Yednock, Ted |
| | | | | Art Unit | 1649 |
| Examiner Name | Emch, Gregory | | | | |
| Attorney Docket Number | 15270C-009820US | | | | |
| Sheet | 23 | of | 27 | | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|--------------------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | 697 | SMALL et al., "Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease," <u>PNAS</u> , 97(11):6037-6042 (2000). | <input type="checkbox"/> |
| | 620 | SOLOMON, B., "Generation and brain delivery of anti-aggregating antibodies against β -amyloid plaques using phage display technology," <u>J. Neural Transm. Suppl.</u> , 62:321-325 (2002). | <input type="checkbox"/> |
| | 621 | SOLOMON, B., "Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease," <u>DNA and Cell Biology</u> , 20(11):697-703 (2001). | <input type="checkbox"/> |
| | 950 | SOLOMON et al., "Fast induction of anti- β -amyloid peptide immune response," <u>Research and Practice in Alzheimer's Disease</u> , 6:260-264 (2002). | <input type="checkbox"/> |
| | 874 | SOTO et al., "The conformation of Alzheimer's beta peptide determines the rate of amyloid formation and its resistance to proteolysis," <u>Biochem. J.</u> , 314:701-707 (1996). | <input type="checkbox"/> |
| | 678 | SOUDER et al., "Overview of Alzheimer's disease," <u>Nurs. Clin. N. Am.</u> , 39:545-559 (2004). | <input type="checkbox"/> |
| | 914 | SPELLERBERG et al., "DNA Vaccines Against Lymphoma," <u>Journal of Immunology</u> , 159:1885-1892 (1997). | <input type="checkbox"/> |
| | 939 | Supplementary Partial European Search Report of 04/10/2007 for European Application 04720353.4-1222. | <input type="checkbox"/> |
| | 907 | TANG et al., "Genetic immunization is a simple method for eliciting an immune response," <u>Nature</u> , 356:152-154 (1992). | <input type="checkbox"/> |
| | 839 | TRAVIS, J., "A Vaccine for Alzheimer's Disease?®," <u>Science News Online</u> , 156(2) pages 1-3 downloaded from internet (1999). | <input type="checkbox"/> |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|---|-----------------|----|----|--------------------------|----------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/544,093 |
| | | | | Filing Date | August 1, 2005 |
| | | | | First Named Inventor | Yednock, Ted |
| | | | | Art Unit | 1649 |
| Examiner Name | Emch, Gregory | | | | |
| Attorney Docket Number | 15270C-009820US | | | | |
| Sheet | 24 | of | 27 | | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|--------------------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | 857 | TRAVIS, J., "Saving the Mind Faces High Hurdles," <u>Science</u> , 309:731-734 (2005). | <input type="checkbox"/> |
| | 767 | TRIEB et al., "APP Peptides Stimulate Lymphocyte Proliferation in Normals, But Not in Patients With Alzheimer's Disease," <u>Neurobiology of Aging</u> , 17(4):541-547 (1996). | <input type="checkbox"/> |
| | 844 | UniProtKB/Swiss-Prot entry P18525, pages 1-3 downloaded from http://www.expasy.org/cgi-bin/niceprot.pl/printable?ac=P18525 on 2/8/97, "HV54_Mouse" (11/1/90). | <input type="checkbox"/> |
| | 815 | URMONEIT et al., "Cerebrovascular Smooth Muscle Cells Internalize Alzheimer Amyloid Beta Protein via a Lipoprotein Pathway: Implications for Cerebral Amyloid Angiopathy," <u>Laboratory Investigation</u> , 77(2):157-166 (1997). | <input type="checkbox"/> |
| | 700 | VALLEIX et al., "Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family," <u>Kidney International</u> , 61:907-912 (2002). | <input type="checkbox"/> |
| | 775 | VAN DEN DOBBELSTEEN et al., "Characteristics of Immune Responses to Native and Protein Conjugated Pneumococcal Polysaccharide Type 14," <u>Scand. J. Immunol.</u> , 41:273-280 (1995). | <input type="checkbox"/> |
| | 835 | VAN LEUVEN, F., "Single and multiple transgenic mice as models for Alzheimer's disease," <u>Progress in Neurobiology</u> , 61:305-312 (2000). | <input type="checkbox"/> |
| | 936 | VANDERSTICHELE et al., "Standardization of Measurement of B-amyloid(1-42) in Cerebrospinal Fluid and Plasma," <u>Int. J. Exp. Clin. Invest.</u> , 7(4):245-258 (2000). | <input type="checkbox"/> |
| | 690 | VICKERS, J. C., "A Vaccine Against Alzheimer's Disease," <u>Drugs Aging</u> , 19(7):487-494 (2002). | <input type="checkbox"/> |
| | 800 | VIDANOVIC et al., "Effects of nonionic surfactants on the physical stability of immunoglobulin G in aqueous solution during mechanical agitation," <u>DIE PHARMAZIE</u> , 58(6):399-404 (2003). | <input type="checkbox"/> |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|---|-----------------|----|----|--------------------------|----------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/544,093 |
| | | | | Filing Date | August 1, 2005 |
| | | | | First Named Inventor | Yednock, Ted |
| | | | | Art Unit | 1649 |
| Examiner Name | Emch, Gregory | | | | |
| Attorney Docket Number | 15270C-009820US | | | | |
| Sheet | 25 | of | 27 | | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|--------------------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | 623 | WALSH et al., "Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo," <u>Nature</u> , 416(6880):535-539 (2002). | <input type="checkbox"/> |
| | 801 | WANG, W., "Instability, stabilization, and formulation of liquid protein pharmaceuticals," <u>Int. J. Pharmaceutics</u> , 185(2):129-188 (1999). | <input type="checkbox"/> |
| | 624 | WASHINGTON UNIVERSITY IN ST. LOUIS SCHOOL OF MEDICINE, "Study gives Clues to Working of Anti-Alzheimer Antibody," downloaded from www.medicine.wustl.edu/~wumpa/news on 12/15/04. | <input type="checkbox"/> |
| | 676 | <i>Webster's New World Dictionary</i> , page 1387, therapeutic (1988). | <input type="checkbox"/> |
| | 688 | <i>Webster's New World Dictionary of American English</i> , Third College Edition, page 1078 (1988). | <input type="checkbox"/> |
| | 765 | WEINER, H. L., "Oral tolerance: immune mechanisms and treatment of autoimmune diseases," <u>Immunology Today</u> , 18:335-343 (1997). | <input type="checkbox"/> |
| | 739 | WEINREB et al., "NACP, A Protein Implicated in Alzheimer's Disease and Learning, Is Natively Unfolded," <u>Biochemistry</u> , 35(43):13709-13715 (1996). | <input type="checkbox"/> |
| | 625 | WHITE et al., "Immunotherapy as a therapeutic treatment for neurodegenerative disorders," <u>J. Neurochem.</u> , 87(4):801-808 (2003). | <input type="checkbox"/> |
| | 749 | Wikipedia definition of "epitope" printed from internet on 4/26/06. | <input type="checkbox"/> |
| | 752 | Wikipedia definition of "antigen" printed from internet on 4/26/06. | <input type="checkbox"/> |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | | |
|--|-----------------|----|----|--------------------------|----------------|--|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | | |
| | | | | Application Number | 10/544,093 | |
| | | | | Filing Date | August 1, 2005 | |
| | | | | First Named Inventor | Yednock, Ted | |
| | | | | Art Unit | 1649 | |
| Examiner Name | Emch, Gregory | | | | | |
| Attorney Docket Number | 15270C-009820US | | | | | |
| Sheet | 26 | of | 27 | | | |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|---|--------------------------|--|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² | |
| | 753 | Wikipedia definition of "route of administration including parenteral" printed from internet on 4/26/06. | <input type="checkbox"/> | |
| | 916 | WINBLAD et al., "Hints of a therapeutic Vaccine for Alzheimer's?" <u>Neuron</u> , 38:517-519 (2003). | <input type="checkbox"/> | |
| | 897 | WHITCOMB et al., "Characterization of saturable binding sites for circulating pancreatic polypeptide in rat brain," <u>Am J Physiol Gastrointest Liver Physiol</u> , 259:G687-G691 (1990). | <input type="checkbox"/> | |
| | 894 | WU et al., "Expression of immunogenic epitopes of hepatitis B surface antigen with hybrid flagellin proteins by a vaccine strain of <i>Salmonella</i> ," <u>PNAS</u> , 86:4726-4730 (1989). | <input type="checkbox"/> | |
| | 900 | Wyeth, Annual Review 2005: Creating Value...Advancing Health (February 27, 2006). | <input type="checkbox"/> | |
| | 909 | XIANG et al., "Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines," <u>Immunity</u> , 2(2):129-135 Abstract (1995). | <input type="checkbox"/> | |
| | 728 | YAMADA et al., "Generation and Characterization of Rat Monoclonal Antibodies Against Human Serum Amyloid A," <u>Scand. J. Immunol.</u> , 46(2):175-179 (1997). | <input type="checkbox"/> | |
| | 917 | YANKNER et al., "Neurotrophic and Neurotoxic effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides," <u>Science</u> , 250:279-282 (1990). | <input type="checkbox"/> | |
| | 793 | ZAMEER et al., "Single Chain Fv Antibodies against 25-35 Peptide Fragment of Amyloid- β : Potential Therapeutic for Alzheimer's Disease," Abstract P4-420, Page S593, presented at Poster Session P4:Therapeutics and Therapeutic Strategies-Therapeutic Strategies, Amyloid-Based, also <u>Neurobiology of Aging</u> , 25(Suppl. 2): p S593 (July 2004). | <input type="checkbox"/> | |
| | 825 | ZHANG et al., "Specialized Applications, Purification of Recombinant Proteins and Study of Protein Interaction by Epitope Tagging," <u>Current Protocols in Mol. Biol.</u> , Supp 41, pages 10.15.1 through 10.15.9 (1998). | <input type="checkbox"/> | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|---|-----------------|----|----|--------------------------|----------------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/544,093 |
| | | | | Filing Date | August 1, 2005 |
| | | | | First Named Inventor | Yednock, Ted |
| | | | | Art Unit | 1649 |
| Examiner Name | Emch, Gregory | | | | |
| Attorney Docket Number | 15270C-009820US | | | | |
| Sheet | 27 | of | 27 | | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|--------------------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | 810 | ZHANG et al., "A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and β -amyloid plaques in a mouse model of Alzheimer's disease," <u>Neurobiology of Disease</u> , 14:365-379 (2003). | <input type="checkbox"/> |

| | | | |
|-----------------------|----------------|--------------------|------------|
| Examiner Signature | /Gregory Emch/ | Date Considered | 02/02/2009 |
|-----------------------|----------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.